Senators want Medicare coverage of lung cancer screen; FDA downgrades pancreatic drainage stent;

@FierceMedDev: Qiagen and Lilly continue successful string of diagnostics partnerships. More | Follow @FierceMedDev

@VarunSaxena2: Medicare will next year have 140,000 different codes, including nine for injuries caused by turkeys. Story from The Economist | Follow @VarunSaxena2

@MichaelGFierce: 'Nanodaisies' carry two cancer drugs and protect them in the bloodstream. Article | Follow @MichaelGFierce

@EmilyWFierce: FDA will hear Sanofi's second plea for Lemtrada approval. Item | Follow @EmilyWFierce

> Senators are urging the Centers for Medicare & Medicaid Services to cover low-dose CT scans for lung cancer screening. Story

> FDA downgraded the regulatory status of pancreatic drainage stents. They can now be cleared via the 510(k) pathway. Story

> FDA allowed the marketing of the first noninvasive test to aid in determining the causes of certain kidney disease. Release

Biotech News

@FierceBiotech: AbbVie heralds early success with its brain cancer-fighting armed antibody. Story | Follow @FierceBiotech

@JohnCFierce: I have to admit, every time I hear something about 'dendritic cells,' I cringe a little. #ASCO14 | Follow @JohnCFierce

@DamianFierce: FT's "usually well informed sources" say $SHPG is eyeing $NPSP. More | Follow @DamianFierce

@EmilyMFierce: BMJ accuses EMA of watering down open trial data policy. Story | Follow @EmilyMFierce

> Can AstraZeneca's cancer pipeline come through on a $12B promise? Story

> Metabolic disease, cardio expert joins Pfizer's R&D team. Chutes & Ladders

Pharma News

@FiercePharma: ICYMI yesterday: The top 10 best-selling vaccines of 2013. Report | Follow @FiercePharma

@TracyStaton: ICYMI, FiercePharma's top weekend news: FDA-nixed diabetes med from Lilly, Boehringer faces rough path to stardom. More | Follow @TracyStaton

@CarlyHFierce: Study: Moral concerns lead barriers to Gardasil uptake in college freshmen. Story from FierceVaccines | Follow @CarlyHFierce

> ASCO tackles a tough question: When is a cancer drug too pricey? More

> Forest spills on Actavis deal details as part of shareholder settlement. Story

> District judge green-lights kickback lawsuit against Novartis. News

Suggested Articles

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.

Saga Diagnostics has raised 40 million Swedish kronor, or about $4.1 million, to help develop its ultrasensitive cancer liquid biopsy tests.

Terumo will help Orchestra BioMed develop its sirolimus-eluting balloon in both coronary and peripheral cardiovascular interventions.